Quark Pharmaceuticals to Present Phase I Data for QPI-1002 in Delayed Graft Function at American Transplant Congress
FREMONT, Calif., May 4, 2010 – Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that data from the Phase I QPI-1002 (I5NP) DGF Study (NCT#00802347) will be presented at the 2010 American Transplant Congress, taking place May 1-5 in San Diego, California. QPI-1002, the first systemically administered siRNA drug […]